Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
STAAR Surgical Community
NasdaqGM:STAA Community
3
Narratives
written by author
0
Comments
on narratives written by author
8
Fair Values set
on narratives written by author
Community Investing Ideas
STAAR Surgical
Popular
Undervalued
Overvalued
STAAR Surgical
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
Key Takeaways Over-reliance on a narrow product portfolio and vulnerability to technological disruption pose significant concentration and innovation risks. Mounting regulatory, geopolitical, and competitive pressures threaten margins, pricing power, and expansion into new global markets.
View narrative
US$16.00
FV
77.3% overvalued
intrinsic discount
12.80%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
STAAR Surgical
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
Key Takeaways Strong demand drivers and strategic innovation position the company for sustained growth and expanding market share, especially as clinical adoption and patient awareness increase. Manufacturing expansion and targeted market development in Asia-Pacific are expected to drive higher profits, improved margins, and operational efficiency.
View narrative
US$28.00
FV
1.3% overvalued
intrinsic discount
25.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
STAAR Surgical
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Introduction Of EVO+ Will Open Market Opportunities In 2025
Key Takeaways Anticipated recovery in China driven by potential demand rebound and new product launch could boost revenue and ASPs. Strong financial position with no debt enables investment in selective growth initiatives and optimization of cash flow management. The company faces challenges from weak macroeconomic conditions in China, reliance on a single distributor model, competitive pressures, and potential impacts from cost-cutting measures.
View narrative
US$22.11
FV
28.3% overvalued
intrinsic discount
8.44%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
12 days ago
author updated this narrative
Your Valuation for
STAA
STAA
STAAR Surgical
Your Fair Value
US$
Current Price
US$28.37
17.4% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-95m
439m
2015
2018
2021
2024
2025
2027
2030
Revenue US$439.3m
Earnings US$63.1m
Advanced
Set Fair Value